eFFECTOR Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q2 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
eFFECTOR Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2020 to Q1 2024.
  • eFFECTOR Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending March 31, 2024 was -$438K, a 8.37% increase year-over-year.
  • eFFECTOR Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending March 31, 2024 was -$1.93M, a 440% decline year-over-year.
  • eFFECTOR Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was -$1.97M, a 120% decline from 2022.
  • eFFECTOR Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $9.74M, a 79.6% decline from 2021.
  • eFFECTOR Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was $47.7M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$1.93M -$438K +$40K +8.37% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$1.97M -$532K +$5K +0.93% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 -$1.97M -$448K -$140K -45.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$1.83M -$509K -$1.48M -153% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$357K -$478K -$10.1M -105% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $9.74M -$537K -$32M -102% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 $41.7M -$308K -$17.9M -102% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $59.6M $966K +$1.47M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $58.2M $9.62M +$10.5M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $47.7M $31.5M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-08
Q3 2021 $17.6M +$17.9M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$504K -$120K -31.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$845K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q3 2020 -$335K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$384K Apr 1, 2020 Jun 30, 2020 8-K 2021-08-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.